Bristol-Myers Squibb (BMY) Tops Q1 EPS by 2c, Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/17/2026
- Generac strikes $8B supply deal with Amazon for data center power
- Wall St ends lower after Fed hikes interest rates, sees more tightening ahead
- Paradium AI (PAAI) Halted, News Pending
- Shipping stocks on fire — but cracks are forming in the rate rally
- JPMorgan Fed scenario analysis: 5 paths for the S&P 500 today
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
April 29, 2022 6:59 AM EDTReports First Quarter Revenues of $11.6 Billion, an Increase of 5% YoY; or 7% When Adjusted for Foreign Exchange Posts First Quarter Earnings Per Share of $0.59 and Non-GAAP EPS of $1.96; Includes Net Impact of ($0.10) per share for GAAP and Non-GAAP EPS Due to Acquired IPRD1 Charges Partially Offset by Licensing Income Delivers Double-Digit Revenue Growth from In-Line Products and New Product Portfolio Advances New Product Portfolio with FDA Approvals for Two First-in-Class Medicines:Â Opdualag in Metastatic Melanoma and Camzyos for Symptomatic Obstructive Hypertrophic Cardiomyopathy Continues to Expand Opdivo... More
